[URL unfurl="true"]https://www.globenewswire.com/news-release/2020/12/07/2140624/0/en/Clarus-Announces-JATENZO-Testosterone-Undecanoate-Capsules-CIII-Now-Covered-by-Express-Scripts.html[/URL]
Clarus Announces JATENZO® (Testosterone Undecanoate) Capsules, CIII Now Covered by Express Scripts
NORTHBROOK, Ill., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc. today announced that Express Scripts, Inc, one of the leading pharmacy benefit managers (PBMs) in the United States will now cover JATENZO® (testosterone undecanoate) capsules, CIII. JATENZO is the first and only FDA-approved oral testosterone undecanoate for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired).1,2 Important Safety Information, including Boxed Warning, is provided below. Limitations of use: Safety and efficacy of JATENZO in males less than 18 years old have not been established.
“This partnership with Express Scripts meaningfully enhances the coverage of JATENZO for patients, and provides appropriate hypogonadal men additional access to an oral testosterone replacement therapy option,” said Dr. Robert Dudley, Chief Executive Officer of Clarus Therapeutics, Inc. “We believe this improved access to JATENZO will give physicians, and their appropriate patients, a convenient oral option for testosterone replacement therapy, and an alternative, not only for new patients but for those patients who are dissatisfied with their current treatment options.”
As of December 1, 2020, nearly 99 million commercial lives, or 61.4% of lives in the U.S., now have access to JATENZO with the addition of Express Scripts. Clarus is committed to working with payers to further broaden JATENZO access for patients and to support patients and providers who desire an oral testosterone replacement therapy option. Clarus also offers patients financial assistance through its JATENZO GO program, where eligible patients with commercial insurance may pay as little as $0 for their monthly prescription of JATENZO. For eligible patients with commercial coverage for JATENZO, their first prescription is free while waiting for insurance verification and prior authorization appeals. Patients can find out more by calling 1-844-269-2795 or visiting the JATENZO website at www.Jatenzo.com for all eligibility requirements.
